; onclick=)
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/romidepsin-uses-dosage-side-effects-interaction_250597.jpg?fit=800%2C600&ssl=1" class="aligncenter wp-post-image" alt="" decoding="async" srcset="https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/romidepsin-uses-dosage-side-effects-interaction_250597.jpg?w=800&ssl=1 800w, https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/romidepsin-uses-dosage-side-effects-interaction_250597.jpg?resize=768%2C576&ssl=1 768w, https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/romidepsin-uses-dosage-side-effects-interaction_250597.jpg?resize=360%2C270&ssl=1 360w, https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/romidepsin-uses-dosage-side-effects-interaction_250597.jpg?resize=600%2C450&ssl=1 600w" sizes="(max-width: 800px) 100vw, 800px" data-attachment-id="255533" data-permalink="https://rxharun.com/rxharun/drug-a-z/romidepsin/attachment/romidepsin-uses-dosage-side-effects-interaction/" data-orig-file="https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/romidepsin-uses-dosage-side-effects-interaction_250597.jpg?fit=800%2C600&ssl=1" data-orig-size="800,600" data-comments-opened="0" data-image-meta="{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="Romidepsin – Uses, Dosage, Side Effects, Interaction" data-image-description="" data-image-caption="" data-medium-file="https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/romidepsin-uses-dosage-side-effects-interaction_250597.jpg?fit=800%2C600&ssl=1" data-large-file="https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/romidepsin-uses-dosage-side-effects-interaction_250597.jpg?fit=800%2C600&ssl=1" data-jpibfi-post-excerpt="" data-jpibfi-post-url="https://rxharun.com/rxharun/drug-a-z/romidepsin/" data-jpibfi-post-title="Romidepsin – Uses, Dosage, Side Effects, Interaction" data-jpibfi-src="https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/romidepsin-uses-dosage-side-effects-interaction_250597.jpg?fit=800%2C600&ssl=1">
Romidepsin is an intravenously administered histone deacetylase inhibitor and antineoplastic agent that is approved for use in refractory or relapsed cutaneous and peripheral T-cell lymphomas. Romidepsin is associated with a modest rate of minor serum enzyme elevations during therapy but has not been linked to cases of clinically apparent liver injury, although it has been reported to cause reactivation of hepatitis B.
Romidepsin is a drug that has been approved by the U.S. Food and Drug Administration (FDA) under the brand name Istodax for the treatment of certain types of cancer. Romidepsin is also being studied as an investigational drug as part of a strategy to cure HIV infection. As an HIV investigational drug, romidepsin belongs to a group of drugs called latency-reversing agents.
Romidepsin is an intravenously administered histone deacetylase inhibitor and antineoplastic agent that is approved for use in refractory or relapsed cutaneous and peripheral T-cell lymphomas. Romidepsin is associated with a modest rate of minor serum enzyme elevations during therapy but has not been linked to cases of clinically apparent liver injury, although it has been reported to cause reactivation of hepatitis B.
Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.
Mechanism of action
Romidepsin is a prodrug, where it becomes active once taken up into the cell. The active metabolite has a free thiol group, which interacts with zinc ions in the active site of class 1 and 2 HDAC enzymes, resulting in inhibition of its enzymatic activity. Certain tumors have over expressed HDACs and downregulated/mutated histone acetyltransferases. This imbalance of HDAC relative to histone acetyltransferase can lead to a decrease in regulatory genes, ensuing tumorigenesis. Inhibition of HDAC may restore normal gene expression in cancer cells and result in cell cycle arrest and apoptosis.
Romidepsin acts as a prodrug with the disulfide bond undergoing reduction within the cell to release a zinc-binding thiol. The thiol binds to a zinc atom in the binding pocket of Zn-dependent histone deacetylase to block its activity. Thus it is an HDAC inhibitor. Many HDAC inhibitors are potential treatments for cancer through the ability to epigenetically restore normal expression of tumor suppressor genes, which may result in cell cycle arrest, differentiation, and apoptosis.[rx]
Indications
- Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms.
- Romidepsin is indicated for the treatment of cutaneous T-cell lymphoma (CTCL) in adult patients who have received at least one prior systemic therapy.[rx]
- Romidepsin is an intravenously administered histone deacetylase inhibitor and antineoplastic agent that is approved for use in refractory or relapsed cutaneous and peripheral T cell lymphomas.
- Romidepsin is a histone deacetylase (HDAC) inhibitor used to treat cutaneous T-cell lymphoma.
- Treatment of peripheral T-cell lymphoma (PTCL),
- Treatment of peripheral T-cell lymphoma (nodal, other extranodal, and leukemic/disseminated).
Romidepsin is used to treat T-cell lymphoma affecting the skin (cutaneous T-cell lymphoma). Romidepsin is given after at least one other cancer treatment did not work or has stopped working. Romidepsin may also be used for purposes not listed in this medication guide.
Use in Cancer
Romidepsin is approved to treat:
- Cutaneous T-cell lymphoma in adults who have already been treated with at least one other type of systemic therapy.
Romidepsin is also being studied in the treatment of other types of cancer
Contraindications
- a bad infection
- low amount of magnesium in the blood
- low amount of potassium in the blood
- anemia
- decreased blood platelets
- low levels of white blood cells
- low levels of a type of white blood cell called neutrophils
- a decreased number of lymphocytes in the blood
- prolonged QT interval on EKG
- abnormal heart rhythm
- abnormal EKG with QT changes from birth
- severe liver disease
- pregnancy
- a patient who is producing milk and breastfeeding
- chronic kidney disease stage 5 (failure)
Dosage
Strengths: 10 mg; 5 mg/mL
Cutaneous T-cell Lymphoma
- 14 mg/m2 IV over 4 hours on days 1, 8, and 15 of a 28-day cycle; repeat cycle every 28 days provided patient continues to benefit and is tolerating therapy.
- For the treatment of cutaneous T-cell Lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL) in patients who have received at least 1 prior systemic therapy.
Peripheral T-cell Lymphoma
- 14 mg/m2 IV over 4 hours on days 1, 8, and 15 of a 28-day cycle; repeat cycle every 28 days provided patient continues to benefit and is tolerating therapy
- For the treatment of cutaneous T-cell Lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL) in patients who have received at least 1 prior systemic therapy.
Dose Adjustments
NONHEMATOLOGIC TOXICITIES (EXCEPT ALOPECIA):
- Grade 2 or 3: Delay therapy until toxicity returns to Grade 1 or less or baseline; resume at 14 mg/m2.
- Grade 3 recurrence: Delay therapy until toxicity returns to Grade 1 or less or baseline; permanently reduce dose to 10 mg/m2.
- Grade 4: Delay therapy until toxicity returns to Grade 1 or less or baseline; permanently reduce dose to 10 mg/m2.
- Grade 3 or 4 recurrence after dose reduction: Discontinue therapy.
HEMATOLOGIC TOXICITIES:
- Grade 3 or 4 neutropenia or thrombocytopenia: Delay therapy until specific cytopenia returns to absolute neutrophil count (ANC) of 1.5 x 10(9)/L or greater and/or platelet count is 75 x 10(9)/L or baseline; restart at 14 mg/m2.
- Grade 4 febrile (38.5C or greater) neutropenia or thrombocytopenia requiring platelet transfusion: Delay therapy until specific cytopenia returns to Grade 1 or less or baseline; permanently reduce dose to 10 mg/m2.
Administration advice:
- Administer IV over a 4-hour period.
- Nausea and vomiting are commonly reported; consider antiemetic support
- Preparation, handling, and disposal should be handled in a manner consistent with safe procedures and handling for cytotoxic drugs.
- Reconstituted solution (5 mg/mL) is chemically stable for up to 8 hours at room temperature.
- Diluted solution is chemically stable for up to 24 hours at room temperature; however, administration as soon as possible following dilution is advised.
- Prolongation of PT and elevation of INR were observed in a patient receiving this drug concomitantly with warfarin. Monitor PT and INR more frequently in these patients.
- Strong CYP450 3A4 inhibitors increase concentrations of this drug. Monitor for toxicity related to increased exposure to this drug and follow the dose modifications for toxicity.
- Rifampin (a potent CYP450 3A4 inducer) increases the concentrations of this drug. Avoid coadministration of this drug with rifampin. The use of other potent CYP450 3A4 inducers should be avoided when possible.
Monitoring:
- Perform ECG at baseline and periodically, especially in patients with a history of significant cardiovascular disease, those on concomitant QT interval prolonging drugs, or those receiving antiarrhythmic drugs.
- Verify normal serum potassium and magnesium levels prior to initiating treatment, and periodically during therapy, especially in higher risk patients.
- Monitor for thrombocytopenia, anemia, neutropenia and lymphopenia during therapy; modify treatment as necessary.
- Monitor patients with advanced stage disease and/or high tumor burden; institute precautions and treat as needed.
Patient advice:
- Report nausea and vomiting to your healthcare provider.
- This drug can lower blood counts and lower resistance to infection; contact your healthcare provider immediately if you experience with signs of infection, significant fatigue, or bleeding.
Side Effects
The Most Common
- nausea
- vomiting
- diarrhea
- constipation
- stomach pain
- mouth sores
- headache
- changed sense of taste
- loss of appetite
- itching
- tiredness or weakness
- pale skin
- shortness of breath
- chest pain
- irregular heartbeat
- feeling dizzy or faint
- easy bruising or bleeding
- fever, cough, flu-like symptoms, muscle aches, burning on urination, worsening skin problems, and other signs of infection (may occur up to 30 days after your treatment)
- rash
- blistering or peeling skin
- swelling of the hands, feet, ankles, or lower legs
More common
- Black, tarry stools
- bleeding gums
- blood in the urine or stools
- blurred vision
- bone pain
- chest pain
- chills
- confusion
- cough
- decreased urine output
- difficulty with breathing
- dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
- drowsiness
- dry mouth
- fast or irregular heartbeat
- fever
- flushed, dry skin
- fruit-like breath odor
- headache
- hoarseness
- increased hunger
- increased thirst
- increased urination
- joint pain, stiffness, or swelling
- loss of appetite
- lower back or side pain
- muscle cramps in the hands, arms, feet, legs, or face
- muscle spasms or twitching
- nausea
- numbness or tingling in the hands, fingertips, feet, or lips
- painful or difficult urination
- pale skin
- pinpoint red spots on the skin
- seizures
- sore throat
- sores, ulcers, or white spots on the lips or in the mouth
- stomach cramps or pain
- sweating
- swelling of the face, ankles, feet, lower legs, or hands
- swollen glands
- tremor
- trouble breathing
- unexplained weight loss
- unusual bleeding or bruising
- unusual tiredness or weakness
- vomiting
Rare
- Change in taste
- constipation
- cracks in the skin
- diarrhea
- itching
- lack or loss of strength
- loss of heat from the body
- loss of taste
- red, swollen skin
- scaly skin
- weight loss
Drug Interactions
| DRUG | INTERACTION |
|---|---|
| Abametapir | The serum concentration of Romidepsin can be increased when it is combined with Abametapir. |
| Abatacept | The metabolism of Romidepsin can be increased when combined with Abatacept. |
| Abemaciclib | The serum concentration of Abemaciclib can be increased when it is combined with Romidepsin. |
| Abrocitinib | The serum concentration of Romidepsin can be increased when it is combined with Abrocitinib. |
| Acalabrutinib | The metabolism of Romidepsin can be decreased when combined with Acalabrutinib. |
| Acenocoumarol | Romidepsin may increase the anticoagulant activities of Acenocoumarol. |
| Acetaminophen | The metabolism of Romidepsin can be increased when combined with Acetaminophen. |
| Acetazolamide | The metabolism of Romidepsin can be decreased when combined with Acetazolamide. |
| Acrivastine | The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Romidepsin. |
| Adalimumab | The metabolism of Romidepsin can be increased when combined with Adalimumab. |
| Adenosine | The risk or severity of QTc prolongation can be increased when Adenosine is combined with Romidepsin. |
| Afatinib | The serum concentration of Romidepsin can be increased when it is combined with Afatinib. |
| Ajmaline | The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Romidepsin. |
| Albendazole | The metabolism of Romidepsin can be decreased when combined with Albendazole. |
| Aldesleukin | The metabolism of Romidepsin can be decreased when combined with Aldesleukin. |
| Alfentanil | The metabolism of Romidepsin can be decreased when combined with Alfentanil. |
| Alfuzosin | The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Romidepsin. |
| Alimemazine | The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Romidepsin. |
| Alpelisib | The metabolism of Romidepsin can be increased when combined with Alpelisib. |
| Alprazolam | The metabolism of Romidepsin can be decreased when combined with Alprazolam. |
| Amantadine | The risk or severity of QTc prolongation can be increased when Amantadine is combined with Romidepsin. |
| Ambrisentan | The serum concentration of Romidepsin can be increased when it is combined with Ambrisentan. |
| Amifampridine | The risk or severity of QTc prolongation can be increased when Amifampridine is combined with Romidepsin. |
| Aminoglutethimide | The metabolism of Romidepsin can be increased when combined with Aminoglutethimide. |
| Amiodarone | The metabolism of Romidepsin can be decreased when combined with Amiodarone. |
| Amisulpride | The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Romidepsin. |
| Amitriptyline | The risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Romidepsin. |
| Amobarbital | The metabolism of Romidepsin can be increased when combined with Amobarbital. |
| Amodiaquine | The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Romidepsin. |
| Amoxapine | The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Romidepsin. |
| Amprenavir | The metabolism of Romidepsin can be decreased when combined with Amprenavir. |
| Anagrelide | The risk or severity of QTc prolongation can be increased when Anagrelide is combined with Romidepsin. |
| Anakinra | The metabolism of Romidepsin can be increased when combined with Anakinra. |
| Antazoline | The risk or severity of QTc prolongation can be increased when Antazoline is combined with Romidepsin. |
| Antipyrine | The metabolism of Romidepsin can be decreased when combined with Antipyrine. |
| Apalutamide | The serum concentration of Romidepsin can be decreased when it is combined with Apalutamide. |
| Apixaban | The serum concentration of Romidepsin can be increased when it is combined with Apixaban. |
| Apomorphine | The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Romidepsin. |
| Apremilast | The metabolism of Romidepsin can be increased when combined with Apremilast. |
| Aprepitant | The metabolism of Romidepsin can be decreased when combined with Aprepitant. |
| Arformoterol | The risk or severity of QTc prolongation can be increased when Arformoterol is combined with Romidepsin. |
| Aripiprazole | The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Romidepsin. |
| Aripiprazole la | The risk or severity of QTc prolongation can be increased when Aripiprazole lauroxil is combined with Romidepsin. |
| Armodafinil | The metabolism of Romidepsin can be increased when combined with Armodafinil. |
| Arsenic trioxide | The serum concentration of Romidepsin can be increased when it is combined with Arsenic trioxide. |
| Artemether | The risk or severity of QTc prolongation can be increased when Romidepsin is combined with Artemether. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Articaine. |
| Asciminib | The serum concentration of Romidepsin can be increased when it is combined with Asciminib. |
| Asenapine | The risk or severity of QTc prolongation can be increased when Romidepsin is combined with Asenapine. |
| Astemizole | The metabolism of Romidepsin can be decreased when combined with Astemizole. |
| Asunaprevir | The serum concentration of Romidepsin can be increased when it is combined with Asunaprevir. |
| Ataluren | The excretion of Romidepsin can be decreased when combined with Ataluren. |
| Atazanavir | The metabolism of Romidepsin can be decreased when combined with Atazanavir. |
| Atomoxetine | The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Romidepsin. |
| Atorvastatin | The metabolism of Romidepsin can be decreased when combined with Atorvastatin. |
| Atropine | The risk or severity of QTc prolongation can be increased when Atropine is combined with Romidepsin. |
| Avacopan | The metabolism of Romidepsin can be decreased when combined with Avacopan. |
| Avanafil | The serum concentration of Avanafil can be increased when it is combined with Romidepsin. |
| Avatrombopag | The serum concentration of Romidepsin can be increased when it is combined with Avatrombopag. |
| Axitinib | The metabolism of Axitinib can be decreased when combined with Romidepsin. |
| Azatadine | The risk or severity of QTc prolongation can be increased when Azatadine is combined with Romidepsin. |
| Azelastine | The metabolism of Romidepsin can be decreased when combined with Azelastine. |
| Azithromycin | The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Romidepsin. |
| Beclomethasone | The metabolism of Romidepsin can be increased when combined with Beclomethasone dipropionate. |
| Bedaquiline | The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Romidepsin. |
| Belantamab mafod | The serum concentration of Romidepsin can be increased when it is combined with Belantamab mafodotin. |
| Belinostat | The serum concentration of Romidepsin can be increased when it is combined with Belinostat. |
| Belumosudil | The serum concentration of Romidepsin can be increased when it is combined with Belumosudil. |
| Belzutifan | The serum concentration of Romidepsin can be decreased when it is combined with Belzutifan. |
| Bempedoic acid | The excretion of Romidepsin can be decreased when combined with Bempedoic acid. |
| Bendamustine | The serum concentration of Bendamustine can be increased when it is combined with Romidepsin. |
| Benzatropine | The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Romidepsin. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Benzocaine. |
| Benzphetamine | The metabolism of Romidepsin can be decreased when combined with Benzphetamine. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Benzyl alcohol. |
| Bepridil | The risk or severity of QTc prolongation can be increased when Bepridil is combined with Romidepsin. |
| Berotralstat | The serum concentration of Romidepsin can be increased when it is combined with Berotralstat. |
| Betamethasone | The metabolism of Romidepsin can be increased when combined with Betamethasone. |
| Betamethasone | The metabolism of Romidepsin can be increased when combined with Betamethasone phosphate. |
| Betrixaban | The serum concentration of Romidepsin can be increased when it is combined with Betrixaban. |
| Bexarotene | The metabolism of Romidepsin can be increased when combined with Bexarotene. |
| Bicalutamide | The metabolism of Romidepsin can be decreased when combined with Bicalutamide. |
| Bifonazole | The metabolism of Romidepsin can be decreased when combined with Bifonazole. |
| Bilastine | The risk or severity of QTc prolongation can be increased when Bilastine is combined with Romidepsin. |
| Bimekizumab | The metabolism of Romidepsin can be increased when combined with Bimekizumab. |
| Binimetinib | The serum concentration of Binimetinib can be increased when it is combined with Romidepsin. |
| Bisoprolol | The serum concentration of Romidepsin can be increased when it is combined with Bisoprolol. |
| Boceprevir | The metabolism of Romidepsin can be decreased when combined with Boceprevir. |
| Bortezomib | The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Romidepsin. |
| Bosentan | The metabolism of Romidepsin can be increased when combined with Bosentan. |
| Bosutinib | The metabolism of Romidepsin can be decreased when combined with Bosutinib. |
| Brentuximab ved | The metabolism of Romidepsin can be decreased when combined with Brentuximab vedotin. |
| Bretylium | The risk or severity of QTc prolongation can be increased when Bretylium is combined with Romidepsin. |
| Brivaracetam | The metabolism of Romidepsin can be decreased when combined with Brivaracetam. |
| Brompheniramine | The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Romidepsin. |
| Buclizine | The risk or severity of QTc prolongation can be increased when Buclizine is combined with Romidepsin. |
| Budesonide | The metabolism of Romidepsin can be increased when combined with Budesonide. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Bupivacaine. |
| Buprenorphine | The metabolism of Romidepsin can be decreased when combined with Buprenorphine. |
| Bupropion | The metabolism of Romidepsin can be decreased when combined with Bupropion. |
| Buserelin | The risk or severity of QTc prolongation can be increased when Buserelin is combined with Romidepsin. |
| Buspirone | The metabolism of Romidepsin can be decreased when combined with Buspirone. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Butacaine. |
| Butalbital | The metabolism of Romidepsin can be increased when combined with Butalbital. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Butamben. |
| Butriptyline | The risk or severity of QTc prolongation can be increased when Butriptyline is combined with Romidepsin. |
| Cabazitaxel | The metabolism of Cabazitaxel can be decreased when combined with Romidepsin. |
| Cabergoline | The serum concentration of Cabergoline can be increased when it is combined with Romidepsin. |
| Calcitriol | The metabolism of Romidepsin can be increased when combined with Calcitriol. |
| Canagliflozin | The serum concentration of Romidepsin can be increased when it is combined with Canagliflozin. |
| Canakinumab | The metabolism of Romidepsin can be increased when combined with Canakinumab. |
| Candicidin | The metabolism of Romidepsin can be decreased when combined with Candicidin. |
| Cannabidiol | The metabolism of Romidepsin can be decreased when combined with Cannabidiol. |
| Capmatinib | The serum concentration of Romidepsin can be increased when it is combined with Capmatinib. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Capsaicin. |
| Carbamazepine | The metabolism of Romidepsin can be increased when combined with Carbamazepine. |
| Carbinoxamine | The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Romidepsin. |
| Carfilzomib | The serum concentration of Romidepsin can be increased when it is combined with Carfilzomib. |
| Carvedilol | The serum concentration of Romidepsin can be increased when it is combined with Carvedilol. |
| Cefradine | The metabolism of Romidepsin can be increased when combined with Cefradine. |
| Celiprolol | The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Romidepsin. |
| Cenobamate | The serum concentration of Romidepsin can be decreased when it is combined with Cenobamate. |
| Cephalexin | The metabolism of Romidepsin can be decreased when combined with Cephalexin. |
| Ceritinib | The metabolism of Romidepsin can be decreased when combined with Ceritinib. |
| Cerivastatin | The metabolism of Romidepsin can be increased when combined with Cerivastatin. |
| Certolizumab pe | The metabolism of Romidepsin can be increased when combined with Certolizumab pegol. |
| Cetirizine | The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Romidepsin. |
| Chloramphenicol | The metabolism of Romidepsin can be decreased when combined with Chloramphenicol. |
| Chlorcyclizine | The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Romidepsin. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Chloroprocaine. |
| Chloroquine | The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Romidepsin. |
| Chlorpheniramine | The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Romidepsin. |
| Chlorpromazine | The metabolism of Romidepsin can be increased when combined with Chlorpromazine. |
| Chlorprothixene | The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Romidepsin. |
| Cilostazol | The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Romidepsin. |
| Cimetidine | The metabolism of Romidepsin can be decreased when combined with Cimetidine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Cinchocaine. |
| Cinnarizine | The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Romidepsin. |
| Cinoxacin | The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Romidepsin. |
| Ciprofloxacin | The metabolism of Romidepsin can be decreased when combined with Ciprofloxacin. |
| Cisapride | The risk or severity of QTc prolongation can be increased when Cisapride is combined with Romidepsin. |
| Cisplatin | The metabolism of Romidepsin can be decreased when combined with Cisplatin. |
| Citalopram | The metabolism of Romidepsin can be decreased when combined with Citalopram. |
| Clarithromycin | The metabolism of Romidepsin can be decreased when combined with Clarithromycin. |
| Clemastine | The risk or severity of QTc prolongation can be increased when Clemastine is combined with Romidepsin. |
| Clevidipine | The metabolism of Romidepsin can be increased when combined with Clevidipine. |
| Clindamycin | The metabolism of Romidepsin can be decreased when combined with Clindamycin. |
| Clobazam | The metabolism of Romidepsin can be increased when combined with Clobazam. |
| Clobetasol prop | The metabolism of Romidepsin can be increased when combined with Clobetasol propionate. |
| Clofazimine | The serum concentration of Romidepsin can be increased when it is combined with Clofazimine. |
| Clofibrate | The metabolism of Romidepsin can be increased when combined with Clofibrate. |
| Clomifene | The serum concentration of Romidepsin can be increased when it is combined with Clomifene. |
| Clomipramine | The risk or severity of QTc prolongation can be increased when Clomipramine is combined with Romidepsin. |
| Clonidine | The metabolism of Clonidine can be decreased when combined with Romidepsin. |
| Clopidogrel | The metabolism of Romidepsin can be decreased when combined with Clopidogrel. |
| Clotiazepam | The metabolism of Romidepsin can be decreased when combined with Clotiazepam. |
| Clozapine | The metabolism of Romidepsin can be increased when combined with Clozapine. |
| Cobicistat | The metabolism of Romidepsin can be decreased when combined with Cobicistat. |
| Cobimetinib | The metabolism of Romidepsin can be decreased when combined with Cobimetinib. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Cocaine. |
| Colchicine | The serum concentration of Romidepsin can be increased when it is combined with Colchicine. |
| Conivaptan | The metabolism of Romidepsin can be decreased when combined with Conivaptan. |
| Copanlisib | The metabolism of Copanlisib can be decreased when combined with Romidepsin. |
| Corticotropin | The metabolism of Romidepsin can be increased when combined with Corticotropin. |
| Cortisone ace | The metabolism of Romidepsin can be increased when combined with Cortisone acetate. |
| Crizotinib | The metabolism of Romidepsin can be decreased when combined with Crizotinib. |
| Curcumin | The metabolism of Romidepsin can be decreased when combined with Curcumin. |
| Cyclizine | The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Romidepsin. |
| Cyclophosphamide | The metabolism of Romidepsin can be increased when combined with Cyclophosphamide. |
| Cyclosporine | The serum concentration of Romidepsin can be increased when it is combined with Cyclosporine. |
| Cyproheptadine | The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Romidepsin. |
| Cyproterone acetate | The metabolism of Romidepsin can be decreased when combined with Cyproterone acetate. |
| Dabigatran etexilate | The serum concentration of Romidepsin can be increased when it is combined with Dabigatran etexilate. |
| Dabrafenib | The serum concentration of Romidepsin can be decreased when it is combined with Dabrafenib. |
| Daclatasvir | The serum concentration of Romidepsin can be increased when it is combined with Daclatasvir. |
| Dacomitinib | The serum concentration of Romidepsin can be increased when it is combined with Dacomitinib. |
| Dactinomycin | The serum concentration of Romidepsin can be increased when it is combined with Dactinomycin. |
| Dalfopristin | The metabolism of Romidepsin can be decreased when combined with Dalfopristin. |
| Danazol | The metabolism of Romidepsin can be decreased when combined with Danazol. |
| Dapsone | The metabolism of Romidepsin can be decreased when combined with Dapsone. |
| Daptomycin | The serum concentration of Romidepsin can be increased when it is combined with Daptomycin. |
| Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Romidepsin. |
| Darolutamide | The serum concentration of Romidepsin can be increased when it is combined with Darolutamide. |
| Darunavir | The serum concentration of Romidepsin can be increased when it is combined with Darunavir. |
| Dasabuvir | The serum concentration of Romidepsin can be increased when it is combined with Dasabuvir. |
| Dasatinib | The metabolism of Romidepsin can be decreased when combined with Dasatinib. |
| Daunorubicin | The metabolism of Romidepsin can be decreased when combined with Daunorubicin. |
| Deferasirox | The metabolism of Romidepsin can be increased when combined with Deferasirox. |
| Deflazacort | The metabolism of Romidepsin can be increased when combined with Deflazacort. |
| Degarelix | The risk or severity of QTc prolongation can be increased when Degarelix is combined with Romidepsin. |
| Delafloxacin | The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Romidepsin. |
| Delamanid | Romidepsin may increase the QTc-prolonging activities of Delamanid. |
| Delavirdine | The metabolism of Romidepsin can be decreased when combined with Delavirdine. |
| Desflurane | The risk or severity of QTc prolongation can be increased when Desflurane is combined with Romidepsin. |
| Desipramine | The metabolism of Romidepsin can be decreased when combined with Desipramine. |
| Desloratadine | The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Romidepsin. |
| Desvenlafaxine | The metabolism of Romidepsin can be decreased when combined with Desvenlafaxine. |
| Deutetrabenazine | The risk or severity of QTc prolongation can be increased when Romidepsin is combined with Deutetrabenazine. |
| Dexamethasone | The metabolism of Romidepsin can be increased when combined with Dexamethasone. |
| Dexamethasone | The serum concentration of Romidepsin can be decreased when it is combined with Dexamethasone acetate. |
| Dexbrompheniram | The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Romidepsin. |
| Dexchlorphenir | The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Romidepsin. |
| Dextromethorphan | The metabolism of Romidepsin can be decreased when combined with Dextromethorphan. |
| Dextropropoxyphene | The metabolism of Romidepsin can be decreased when combined with Dextropropoxyphene. |
| Diazepam | The metabolism of Romidepsin can be decreased when combined with Diazepam. |
| Diclofenac | The metabolism of Romidepsin can be decreased when combined with Diclofenac. |
| Dicloxacillin | The metabolism of Romidepsin can be increased when combined with Dicloxacillin. |
| Diethylstilbestrol | The metabolism of Romidepsin can be decreased when combined with Diethylstilbestrol. |
| Difluocortolone | The metabolism of Romidepsin can be increased when combined with Difluocortolone. |
| Digitoxin | The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Romidepsin. |
| Digoxin | The risk or severity of QTc prolongation can be increased when Digoxin is combined with Romidepsin. |
| Dihydroergocornine | The metabolism of Romidepsin can be decreased when combined with Dihydroergocornine. |
| Dihydroergocristine | The metabolism of Romidepsin can be decreased when combined with Dihydroergocristine. |
| Dihydroergotamine | The metabolism of Romidepsin can be decreased when combined with Dihydroergotamine. |
| Diltiazem | The metabolism of Romidepsin can be decreased when combined with Diltiazem. |
| Dimenhydrinate | The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Romidepsin. |
| Dimethyl sulfoxide | The metabolism of Romidepsin can be decreased when combined with Dimethyl sulfoxide. |
| Diosmin | The serum concentration of Romidepsin can be increased when it is combined with Diosmin. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Diphenhydramine. |
| Dipyridamole | The excretion of Romidepsin can be decreased when combined with Dipyridamole. |
| Disopyramide | The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Romidepsin. |
| Disulfiram | The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Romidepsin. |
| Docetaxel | The metabolism of Romidepsin can be decreased when combined with Docetaxel. |
| Dofetilide | The risk or severity of QTc prolongation can be increased when Dofetilide is combined with Romidepsin. |
| Dolasetron | The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Romidepsin. |
| Dolutegravir | The serum concentration of Romidepsin can be increased when it is combined with Dolutegravir. |
| Domperidone | The risk or severity of QTc prolongation can be increased when Domperidone is combined with Romidepsin. |
| Doravirine | The metabolism of Doravirine can be decreased when combined with Romidepsin. |
| Dosulepin | The metabolism of Dosulepin can be decreased when combined with Romidepsin. |
| Doxazosin | The metabolism of Romidepsin can be decreased when combined with Doxazosin. |
| Doxepin | The risk or severity of QTc prolongation can be increased when Doxepin is combined with Romidepsin. |
| Doxorubicin | The metabolism of Romidepsin can be decreased when combined with Doxorubicin. |
| Doxylamine | The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Romidepsin. |
| Dronabinol | The metabolism of Romidepsin can be decreased when combined with Dronabinol. |
| Dronedarone | Romidepsin may increase the QTc-prolonging activities of Dronedarone. |
| Droperidol | The risk or severity of QTc prolongation can be increased when Droperidol is combined with Romidepsin. |
| Drospirenone | The metabolism of Romidepsin can be decreased when combined with Drospirenone. |
| Dutasteride | The metabolism of Romidepsin can be decreased when combined with Dutasteride. |
| Duvelisib | The metabolism of Romidepsin can be decreased when combined with Duvelisib. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Dyclonine. |
| Ebastine | The metabolism of Romidepsin can be decreased when combined with Ebastine. |
| Echinacea | The metabolism of Romidepsin can be increased when combined with Echinacea. |
| Edoxaban | The serum concentration of Romidepsin can be increased when it is combined with Edoxaban. |
| Efavirenz | The metabolism of Romidepsin can be decreased when combined with Efavirenz. |
| Elagolix | The serum concentration of Romidepsin can be increased when it is combined with Elagolix. |
| Elbasvir | The serum concentration of Romidepsin can be increased when it is combined with Elbasvir. |
| Elexacaftor | The metabolism of Romidepsin can be decreased when combined with Elexacaftor. |
| Eliglustat | The serum concentration of Romidepsin can be increased when it is combined with Eliglustat. |
| Elvitegravir | The metabolism of Romidepsin can be decreased when combined with Elvitegravir. |
| Emapalumab | The metabolism of Romidepsin can be increased when combined with Emapalumab. |
| Emedastine | The risk or severity of QTc prolongation can be increased when Emedastine is combined with Romidepsin. |
| Enasidenib | The serum concentration of Romidepsin can be increased when it is combined with Enasidenib. |
| Encainide | The risk or severity of QTc prolongation can be increased when Encainide is combined with Romidepsin. |
| Encorafenib | The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Romidepsin. |
| Enfortumab vedotin | The serum concentration of Romidepsin can be increased when it is combined with Enfortumab vedotin. |
| Enoxacin | The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Romidepsin. |
| Entrectinib | The risk or severity of QTc prolongation can be increased when Romidepsin is combined with Entrectinib. |
| Enzalutamide | The serum concentration of Romidepsin can be decreased when it is combined with Enzalutamide. |
| Epinastine | The risk or severity of QTc prolongation can be increased when Epinastine is combined with Romidepsin. |
| Epinephrine | The metabolism of Romidepsin can be decreased when combined with Epinephrine. |
| Eplerenone | The metabolism of Romidepsin can be decreased when combined with Eplerenone. |
| Erdafitinib | The serum concentration of Romidepsin can be increased when it is combined with Erdafitinib. |
| Ergotamine | The metabolism of Romidepsin can be decreased when combined with Ergotamine. |
| Eribulin | The risk or severity of QTc prolongation can be increased when Eribulin is combined with Romidepsin. |
| Erlotinib | The metabolism of Romidepsin can be decreased when combined with Erlotinib. |
| Ertugliflozin | The serum concentration of Romidepsin can be increased when it is combined with Ertugliflozin. |
| Erythromycin | The serum concentration of Romidepsin can be increased when it is combined with Erythromycin. |
| Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Romidepsin. |
| Escitalopram | The risk or severity of QTc prolongation can be increased when Escitalopram is combined with Romidepsin. |
| Esketamine | The metabolism of Romidepsin can be increased when combined with Esketamine. |
| Eslicarbazepine | The metabolism of Romidepsin can be increased when combined with Eslicarbazepine. |
| Eslicarbazepine | The metabolism of Romidepsin can be increased when combined with Eslicarbazepine acetate. |
| Esmolol | The risk or severity of QTc prolongation can be increased when Esmolol is combined with Romidepsin. |
| Estetrol | The metabolism of Romidepsin can be decreased when combined with Estetrol. |
| Estradiol | The metabolism of Romidepsin can be decreased when combined with Estradiol. |
| Estradiol acetate | The metabolism of Romidepsin can be increased when combined with Estradiol acetate. |
| Estradiol benzoate | The metabolism of Romidepsin can be increased when combined with Estradiol benzoate. |
| Estradiol cypionate | The metabolism of Romidepsin can be increased when combined with Estradiol cypionate. |
| Estradiol dienanth | The metabolism of Romidepsin can be increased when combined with Estradiol dienanthate. |
| Estradiol valerate | The metabolism of Romidepsin can be increased when combined with Estradiol valerate. |
| Etanercept | The metabolism of Romidepsin can be increased when combined with Etanercept. |
| Ethambutol | The metabolism of Romidepsin can be decreased when combined with Ethambutol. |
| Ethanol | The metabolism of Romidepsin can be increased when combined with Ethanol. |
| Ethinylestradiol | The metabolism of Romidepsin can be decreased when combined with Ethinylestradiol. |
| Ethosuximide | The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Romidepsin. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Ethyl chloride. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Etidocaine. |
| Etoposide | The metabolism of Etoposide can be decreased when combined with Romidepsin. |
| Etoricoxib | The metabolism of Romidepsin can be decreased when combined with Etoricoxib. |
| Etravirine | The metabolism of Romidepsin can be increased when combined with Etravirine. |
| Everolimus | The serum concentration of Romidepsin can be increased when it is combined with Everolimus. |
| Ezogabine | The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Romidepsin. |
| Famotidine | The risk or severity of QTc prolongation can be increased when Famotidine is combined with Romidepsin. |
| Favipiravir | The serum concentration of Romidepsin can be increased when it is combined with Favipiravir. |
| Fedratinib | The serum concentration of Romidepsin can be increased when it is combined with Fedratinib. |
| Felbamate | The metabolism of Romidepsin can be increased when combined with Felbamate. |
| Felodipine | The risk or severity of QTc prolongation can be increased when Felodipine is combined with Romidepsin. |
| Fenfluramine | The metabolism of Romidepsin can be decreased when combined with Fenfluramine. |
| Fenofibrate | The metabolism of Romidepsin can be decreased when combined with Fenofibrate. |
| Fexinidazole | The risk or severity of adverse effects can be increased when Romidepsin is combined with Fexinidazole. |
| Fexofenadine | The serum concentration of Romidepsin can be increased when it is combined with Fexofenadine. |
| Filgotinib | The serum concentration of Romidepsin can be increased when it is combined with Filgotinib. |
| Finasteride | The metabolism of Romidepsin can be decreased when combined with Finasteride. |
| Flecainide | The risk or severity of QTc prolongation can be increased when Flecainide is combined with Romidepsin. |
| Flibanserin | The serum concentration of Romidepsin can be increased when it is combined with Flibanserin. |
| Flucloxacillin | The metabolism of Romidepsin can be increased when combined with Flucloxacillin. |
| Fluconazole | The serum concentration of Romidepsin can be increased when it is combined with Fluconazole. |
| Flunisolide | The metabolism of Romidepsin can be increased when combined with Flunisolide. |
| Flunitrazepam | The metabolism of Romidepsin can be decreased when combined with Flunitrazepam. |
| Fluocinolone ace | The metabolism of Romidepsin can be increased when combined with Fluocinolone acetonide. |
| Fluocinonide | The metabolism of Romidepsin can be increased when combined with Fluocinonide. |
| Fluocortolone | The metabolism of Romidepsin can be increased when combined with Fluocortolone. |
| Fluorouracil | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Romidepsin. |
| Fluoxetine | The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Romidepsin. |
| Flupentixol | The risk or severity of QTc prolongation can be increased when Flupentixol is combined with Romidepsin. |
| Fluspirilene | The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Romidepsin. |
| Flutamide | The metabolism of Romidepsin can be decreased when combined with Flutamide. |
| Fluticasone | The metabolism of Romidepsin can be increased when combined with Fluticasone. |
| Fluticasone fu | The metabolism of Fluticasone furoate can be decreased when combined with Romidepsin. |
| Fluticasone pr | The metabolism of Romidepsin can be decreased when combined with Fluticasone propionate. |
| Fluvastatin | The metabolism of Romidepsin can be increased when combined with Fluvastatin. |
| Fluvoxamine | The metabolism of Romidepsin can be decreased when combined with Fluvoxamine. |
| Formestane | The metabolism of Romidepsin can be increased when combined with Formestane. |
| Formoterol | The risk or severity of QTc prolongation can be increased when Formoterol is combined with Romidepsin. |
| Fosamprenavir | The metabolism of Romidepsin can be decreased when combined with Fosamprenavir. |
| Fosaprepitant | The metabolism of Romidepsin can be increased when combined with Fosaprepitant. |
| Foscarnet | The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Romidepsin. |
| Fosnetupitant | The metabolism of Romidepsin can be decreased when combined with Fosnetupitant. |
| Fosphenytoin | The metabolism of Romidepsin can be increased when combined with Fosphenytoin. |
| Fostamatinib | The metabolism of Romidepsin can be decreased when combined with Fostamatinib. |
| Fostemsavir | The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Romidepsin. |
| Fusidic acid | The metabolism of Romidepsin can be decreased when combined with Fusidic acid. |
| Futibatinib | The serum concentration of Romidepsin can be increased when it is combined with Futibatinib. |
| Gadobenic acid | The risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Romidepsin. |
| Galantamine | The risk or severity of QTc prolongation can be increased when Galantamine is combined with Romidepsin. |
| Gatifloxacin | The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Romidepsin. |
| Gefitinib | The metabolism of Romidepsin can be decreased when combined with Gefitinib. |
| Gemcitabine | The serum concentration of Romidepsin can be increased when it is combined with Gemcitabine. |
| Gemfibrozil | The excretion of Romidepsin can be decreased when combined with Gemfibrozil. |
| Gemifloxacin | The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Romidepsin. |
| Gilteritinib | The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Romidepsin. |
| Ginkgo biloba | The metabolism of Romidepsin can be decreased when combined with Ginkgo biloba. |
| Glasdegib | The serum concentration of Romidepsin can be increased when it is combined with Glasdegib. |
| Glecaprevir | The serum concentration of Romidepsin can be increased when it is combined with Glecaprevir. |
| Glyburide | The metabolism of Romidepsin can be decreased when combined with Glyburide. |
| Glycerol phenylbu | The metabolism of Romidepsin can be increased when combined with Glycerol phenylbutyrate. |
| Golimumab | The metabolism of Romidepsin can be increased when combined with Golimumab. |
| Goserelin | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Romidepsin. |
| Granisetron | The risk or severity of QTc prolongation can be increased when Granisetron is combined with Romidepsin. |
| Grazoprevir | The serum concentration of Romidepsin can be increased when it is combined with Grazoprevir. |
| Grepafloxacin | The risk or severity of QTc prolongation can be increased when Grepafloxacin is combined with Romidepsin. |
| Griseofulvin | The metabolism of Romidepsin can be increased when combined with Griseofulvin. |
| Halofantrine | The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Romidepsin. |
| Haloperidol | The risk or severity of QTc prolongation can be increased when Romidepsin is combined with Haloperidol. |
| Halothane | The metabolism of Romidepsin can be decreased when combined with Halothane. |
| Histrelin | The risk or severity of QTc prolongation can be increased when Histrelin is combined with Romidepsin. |
| Hydralazine | The metabolism of Romidepsin can be decreased when combined with Hydralazine. |
| Hydrochlorothiazide | The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Romidepsin. |
| Hydrocodone | The metabolism of Romidepsin can be decreased when combined with Hydrocodone. |
| Hydrocortamate | The metabolism of Romidepsin can be increased when combined with Hydrocortamate. |
| Hydrocortisone | The metabolism of Romidepsin can be increased when combined with Hydrocortisone. |
| Hydrocortisone a | The metabolism of Romidepsin can be increased when combined with Hydrocortisone acetate. |
| Hydrocortisone butyr | The metabolism of Romidepsin can be increased when combined with Hydrocortisone butyrate. |
| Hydrocortisone c | The metabolism of Hydrocortisone cypionate can be decreased when combined with Romidepsin. |
| Hydrocortisone phos | The metabolism of Hydrocortisone phosphate can be decreased when combined with Romidepsin. |
| Hydrocortisone succi | The metabolism of Romidepsin can be increased when combined with Hydrocortisone succinate. |
| Hydroxychloroquine | The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Romidepsin. |
| Hydroxyprogesterone | The metabolism of Hydroxyprogesterone caproate can be decreased when combined with Romidepsin. |
| Hydroxyzine | The risk or severity of QTc prolongation can be increased when Romidepsin is combined with Hydroxyzine. |
| Hyoscyamine | The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Romidepsin. |
| Ibandronate | The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Romidepsin. |
| Ibrutinib | The metabolism of Ibrutinib can be decreased when combined with Romidepsin. |
| Ibutilide | The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Romidepsin. |
| Idelalisib | The metabolism of Romidepsin can be decreased when combined with Idelalisib. |
| Ifosfamide | The metabolism of Romidepsin can be increased when combined with Ifosfamide. |
| Iloperidone | The risk or severity of QTc prolongation can be increased when Iloperidone is combined with Romidepsin. |
| Imatinib | The serum concentration of Romidepsin can be increased when it is combined with Imatinib. |
| Imipramine | The risk or severity of QTc prolongation can be increased when Imipramine is combined with Romidepsin. |
| Indacaterol | The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Romidepsin. |
| Indapamide | The risk or severity of QTc prolongation can be increased when Indapamide is combined with Romidepsin. |
| Indinavir | The metabolism of Romidepsin can be decreased when combined with Indinavir. |
| Infigratinib | The metabolism of Romidepsin can be decreased when combined with Infigratinib. |
| Infliximab | The metabolism of Romidepsin can be increased when combined with Infliximab. |
| Inotersen | The risk or severity of QTc prolongation can be increased when Inotersen is combined with Romidepsin. |
| Inotuzumab ozog | The serum concentration of Romidepsin can be increased when it is combined with Inotuzumab ozogamicin. |
| Irbesartan | The metabolism of Romidepsin can be decreased when combined with Irbesartan. |
| Irinotecan | The metabolism of Romidepsin can be decreased when combined with Irinotecan. |
| Isavuconazole | The serum concentration of Romidepsin can be increased when it is combined with Isavuconazole. |
| Isavuconazonium | The serum concentration of Romidepsin can be increased when it is combined with Isavuconazonium. |
| Isoflurane | The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Romidepsin. |
| Isoniazid | The metabolism of Romidepsin can be decreased when combined with Isoniazid. |
| Isradipine | The metabolism of Romidepsin can be decreased when combined with Isradipine. |
| Istradefylline | The serum concentration of Romidepsin can be increased when it is combined with Istradefylline. |
| Itraconazole | The metabolism of Romidepsin can be decreased when combined with Itraconazole. |
| Ivabradine | The risk or severity of QTc prolongation can be increased when Romidepsin is combined with Ivabradine. |
| Ivacaftor | The serum concentration of Romidepsin can be increased when it is combined with Ivacaftor. |
| Ivermectin | The excretion of Romidepsin can be decreased when combined with Ivermectin. |
| Ivosidenib | The risk or severity of QTc prolongation can be increased when Romidepsin is combined with Ivosidenib. |
| Ixabepilone | The serum concentration of Romidepsin can be increased when it is combined with Ixabepilone. |
| Ketamine | The metabolism of Romidepsin can be decreased when combined with Ketamine. |
| Ketazolam | The metabolism of Romidepsin can be decreased when combined with Ketazolam. |
| Ketoconazole | The metabolism of Romidepsin can be decreased when combined with Ketoconazole. |
| Lacidipine | The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Romidepsin. |
| Lacosamide | The metabolism of Romidepsin can be decreased when combined with Lacosamide. |
| Lamotrigine | The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Romidepsin. |
| Lanreotide | The metabolism of Romidepsin can be decreased when combined with Lanreotide. |
| Lapatinib | The serum concentration of Romidepsin can be increased when it is combined with Lapatinib. |
| Larotrectinib | The serum concentration of Romidepsin can be increased when it is combined with Larotrectinib. |
| Lasmiditan | The serum concentration of Romidepsin can be increased when it is combined with Lasmiditan. |
| Ledipasvir | The serum concentration of Romidepsin can be increased when it is combined with Ledipasvir. |
| Lefamulin | Lefamulin may increase the QTc-prolonging activities of Romidepsin. |
| Lemborexant | The serum concentration of Romidepsin can be decreased when it is combined with Lemborexant. |
| Lenvatinib | The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Romidepsin. |
| Lercanidipine | The metabolism of Romidepsin can be decreased when combined with Lercanidipine. |
| Lesinurad | The metabolism of Romidepsin can be increased when combined with Lesinurad. |
| Letermovir | The metabolism of Romidepsin can be decreased when combined with Letermovir. |
| Leuprolide | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Romidepsin. |
| Levacetylme | The risk or severity of QTc prolongation can be increased when Levacetylmethadol is combined with Romidepsin. |
| Levamlodipine | The metabolism of Levamlodipine can be decreased when combined with Romidepsin. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Levobupivacaine. |
| Levocabastine | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Romidepsin. |
| Levocetirizine | The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Romidepsin. |
| Levofloxacin | The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Romidepsin. |
| Levoketoconazole | The metabolism of Romidepsin can be decreased when combined with Levoketoconazole. |
| Levomenthol | The risk or severity of QTc prolongation can be increased when Levomenthol is combined with Romidepsin. |
| Levonorgestrel | The metabolism of Romidepsin can be decreased when combined with Levonorgestrel. |
| Levosimendan | The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Romidepsin. |
| Levothyroxine | The serum concentration of Romidepsin can be decreased when it is combined with Levothyroxine. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Lidocaine. |
| Lidoflazine | The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Romidepsin. |
| Linagliptin | The serum concentration of Romidepsin can be increased when it is combined with Linagliptin. |
| Lofexidine | The risk or severity of QTc prolongation can be increased when Lofexidine is combined with Romidepsin. |
| Lomefloxacin | The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Romidepsin. |
| Lomitapide | The serum concentration of Romidepsin can be increased when it is combined with Lomitapide. |
| Lonafarnib | The metabolism of Romidepsin can be decreased when combined with Lonafarnib. |
| Loncastuximab | The serum concentration of Romidepsin can be increased when it is combined with Loncastuximab tesirine. |
| Loperamide | The risk or severity of QTc prolongation can be increased when Loperamide is combined with Romidepsin. |
| Lopinavir | The metabolism of Romidepsin can be decreased when combined with Lopinavir. |
| Lorcaserin | The metabolism of Romidepsin can be decreased when combined with Lorcaserin. |
| Lorlatinib | The serum concentration of Romidepsin can be decreased when it is combined with Lorlatinib. |
| Losartan | The metabolism of Romidepsin can be decreased when combined with Losartan. |
| Lovastatin | The metabolism of Romidepsin can be decreased when combined with Lovastatin. |
| Loxapine | The serum concentration of Romidepsin can be increased when it is combined with Loxapine. |
| Lumacaftor | The serum concentration of Romidepsin can be decreased when it is combined with Lumacaftor. |
| Lumefantrine | The risk or severity of QTc prolongation can be increased when Romidepsin is combined with Lumefantrine. |
| Lurasidone | The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Romidepsin. |
| Lusutrombopag | The serum concentration of Romidepsin can be increased when it is combined with Lusutrombopag. |
| Macimorelin | The risk or severity of QTc prolongation can be increased when Romidepsin is combined with Macimorelin. |
| Manidipine | The metabolism of Romidepsin can be decreased when combined with Manidipine. |
| Mannitol | The serum concentration of Romidepsin can be increased when it is combined with Mannitol. |
| Maprotiline | The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Romidepsin. |
| Maribavir | The serum concentration of Romidepsin can be increased when it is combined with Maribavir. |
| Mavacamten | The serum concentration of Romidepsin can be decreased when it is combined with Mavacamten. |
| Medroxyproge | The metabolism of Romidepsin can be increased when combined with Medroxyprogesterone acetate. |
| Mefloquine | The serum concentration of Romidepsin can be increased when it is combined with Mefloquine. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Meloxicam. |
| Memantine | The metabolism of Romidepsin can be decreased when combined with Memantine. |
| Meperidine | The metabolism of Romidepsin can be decreased when combined with Meperidine. |
| Mephenytoin | The metabolism of Romidepsin can be decreased when combined with Mephenytoin. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Mepivacaine. |
| Meprednisone | The metabolism of Romidepsin can be increased when combined with Meprednisone. |
| Mepyramine | The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Romidepsin. |
| Mesoridazine | The risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Romidepsin. |
| Methadone | The metabolism of Romidepsin can be decreased when combined with Methadone. |
| Methimazole | The metabolism of Romidepsin can be decreased when combined with Methimazole. |
| Methotrimeprazine | The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Romidepsin. |
| Methoxy | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Romidepsin. |
| Methoxyflurane | The metabolism of Romidepsin can be decreased when combined with Methoxyflurane. |
| Methsuximide | The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Romidepsin. |
| Methylene blue | The serum concentration of Romidepsin can be increased when it is combined with Methylene blue. |
| Methylergometrine | The metabolism of Romidepsin can be decreased when combined with Methylergometrine. |
| Methylphenobarbital | The metabolism of Romidepsin can be increased when combined with Methylphenobarbital. |
| Methylprednisolone | The metabolism of Romidepsin can be increased when combined with Methylprednisolone. |
| Methylprednisone | The metabolism of Romidepsin can be decreased when combined with Methylprednisone. |
| Methyltestosterone | The metabolism of Methyltestosterone can be decreased when combined with Romidepsin. |
| Methysergide | The metabolism of Romidepsin can be decreased when combined with Methysergide. |
| Metoclopramide | The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Romidepsin. |
| Metreleptin | The metabolism of Romidepsin can be increased when combined with Metreleptin. |
| Metronidazole | The metabolism of Romidepsin can be decreased when combined with Metronidazole. |
| Metyrapone | The metabolism of Romidepsin can be increased when combined with Metyrapone. |
| Mexiletine | The metabolism of Romidepsin can be decreased when combined with Mexiletine. |
| Mianserin | The metabolism of Romidepsin can be decreased when combined with Mianserin. |
| Miconazole | The metabolism of Romidepsin can be decreased when combined with Miconazole. |
| Midazolam | The metabolism of Romidepsin can be decreased when combined with Midazolam. |
| Midostaurin | The metabolism of Romidepsin can be decreased when combined with Midostaurin. |
| Mifepristone | The serum concentration of Romidepsin can be decreased when it is combined with Mifepristone. |
| Milnacipran | The metabolism of Romidepsin can be decreased when combined with Milnacipran. |
| Miocamycin | The metabolism of Romidepsin can be decreased when combined with Miocamycin. |
| Mirabegron | The serum concentration of Romidepsin can be increased when it is combined with Mirabegron. |
| Mirtazapine | The metabolism of Romidepsin can be decreased when combined with Mirtazapine. |
| Mitapivat | The metabolism of Romidepsin can be increased when combined with Mitapivat. |
| Mitotane | The metabolism of Romidepsin can be increased when combined with Mitotane. |
| Mizolastine | The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Romidepsin. |
| Mobocertinib | The risk or severity of QTc prolongation can be increased when Romidepsin is combined with Mobocertinib. |
| Modafinil | The metabolism of Romidepsin can be increased when combined with Modafinil. |
| Moexipril | The risk or severity of QTc prolongation can be increased when Moexipril is combined with Romidepsin. |
| Mometasone furoate | The metabolism of Romidepsin can be increased when combined with Mometasone furoate. |
| Moricizine | The risk or severity of QTc prolongation can be increased when Moricizine is combined with Romidepsin. |
| Morphine | The serum concentration of Romidepsin can be increased when it is combined with Morphine. |
| Mosunetuzumab | The metabolism of Romidepsin can be decreased when combined with Mosunetuzumab. |
| Moxifloxacin | The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Romidepsin. |
| Mycophenolate | The metabolism of Romidepsin can be decreased when combined with Mycophenolate mofetil. |
| Nafcillin | The metabolism of Romidepsin can be increased when combined with Nafcillin. |
| Nalidixic acid | The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Romidepsin. |
| Nateglinide | The metabolism of Romidepsin can be decreased when combined with Nateglinide. |
| Nefazodone | The metabolism of Romidepsin can be decreased when combined with Nefazodone. |
| Nelfinavir | The metabolism of Romidepsin can be decreased when combined with Nelfinavir. |
| Neratinib | The serum concentration of Romidepsin can be increased when it is combined with Neratinib. |
| Netupitant | The serum concentration of Romidepsin can be increased when it is combined with Netupitant. |
| Nevirapine | The metabolism of Romidepsin can be increased when combined with Nevirapine. |
| Niacin | The metabolism of Romidepsin can be decreased when combined with Niacin. |
| Nicardipine | The metabolism of Romidepsin can be decreased when combined with Nicardipine. |
| Nicotine | The metabolism of Romidepsin can be decreased when combined with Nicotine. |
| Nifedipine | The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Romidepsin. |
| Nilotinib | The metabolism of Romidepsin can be decreased when combined with Nilotinib. |
| Nilvadipine | The metabolism of Romidepsin can be decreased when combined with Nilvadipine. |
| Nimodipine | The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Romidepsin. |
| Nintedanib | The metabolism of Romidepsin can be decreased when combined with Nintedanib. |
| Nisoldipine | The metabolism of Romidepsin can be decreased when combined with Nisoldipine. |
| Nitrendipine | The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Romidepsin. |
| Norethisterone | The metabolism of Romidepsin can be decreased when combined with Norethisterone. |
| Norfloxacin | The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Romidepsin. |
| Norgestimate | The serum concentration of Romidepsin can be increased when it is combined with Norgestimate. |
| Nortriptyline | The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Romidepsin. |
| Noscapine | The metabolism of Romidepsin can be decreased when combined with Noscapine. |
| Novobiocin | The excretion of Romidepsin can be decreased when combined with Novobiocin. |
| Nystatin | The excretion of Romidepsin can be decreased when combined with Nystatin. |
| Octreotide | The serum concentration of Romidepsin can be increased when it is combined with Octreotide. |
| Ofloxacin | The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Romidepsin. |
| Olanzapine | The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Romidepsin. |
| Olaparib | The metabolism of Romidepsin can be decreased when combined with Olaparib. |
| Olodaterol | The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Romidepsin. |
| Omadacycline | The serum concentration of Romidepsin can be increased when it is combined with Omadacycline. |
| Ombitasvir | The serum concentration of Romidepsin can be increased when it is combined with Ombitasvir. |
| Ondansetron | The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Romidepsin. |
| Oritavancin | The metabolism of Romidepsin can be increased when combined with Oritavancin. |
| Orphenadrine | The metabolism of Romidepsin can be decreased when combined with Orphenadrine. |
| Osilodrostat | The metabolism of Romidepsin can be decreased when combined with Osilodrostat. |
| Osimertinib | The metabolism of Romidepsin can be decreased when combined with Osimertinib. |
| Ospemifene | The metabolism of Romidepsin can be decreased when combined with Ospemifene. |
| Oxaliplatin | The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Romidepsin. |
| Oxatomide | The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Romidepsin. |
| Oxcarbazepine | The metabolism of Romidepsin can be increased when combined with Oxcarbazepine. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Oxetacaine. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Oxybuprocaine. |
| Oxybutynin | The metabolism of Romidepsin can be decreased when combined with Oxybutynin. |
| Oxycodone | The metabolism of Romidepsin can be decreased when combined with Oxycodone. |
| Oxytocin | The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Romidepsin. |
| Paclitaxel | The metabolism of Romidepsin can be increased when combined with Paclitaxel. |
| Pacritinib | The serum concentration of Romidepsin can be increased when it is combined with Pacritinib. |
| Palbociclib | The serum concentration of Romidepsin can be increased when it is combined with Palbociclib. |
| Paliperidone | The serum concentration of Romidepsin can be increased when it is combined with Paliperidone. |
| Panobinostat | The risk or severity of QTc prolongation can be increased when Panobinostat is combined with Romidepsin. |
| Papaverine | The risk or severity of QTc prolongation can be increased when Papaverine is combined with Romidepsin. |
| Paritaprevir | The serum concentration of Romidepsin can be increased when it is combined with Paritaprevir. |
| Paroxetine | The metabolism of Romidepsin can be decreased when combined with Paroxetine. |
| Pasireotide | The metabolism of Romidepsin can be decreased when combined with Pasireotide. |
| Pazopanib | The metabolism of Romidepsin can be decreased when combined with Pazopanib. |
| Pefloxacin | The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Romidepsin. |
| Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with Romidepsin. |
| Pentamidine | The risk or severity of QTc prolongation can be increased when Pentamidine is combined with Romidepsin. |
| Pentobarbital | The metabolism of Romidepsin can be increased when combined with Pentobarbital. |
| Perampanel | The metabolism of Romidepsin can be increased when combined with Perampanel. |
| Perflutren | The risk or severity of QTc prolongation can be increased when Perflutren is combined with Romidepsin. |
| Perhexiline | The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Romidepsin. |
| Pexidartinib | The excretion of Romidepsin can be decreased when combined with Pexidartinib. |
| Pheniramine | The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Romidepsin. |
| Phenobarbital | The metabolism of Romidepsin can be increased when combined with Phenobarbital. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Phenol. |
| Phenylbutazone | The metabolism of Romidepsin can be increased when combined with Phenylbutazone. |
| Phenytoin | The metabolism of Romidepsin can be increased when combined with Phenytoin. |
| Pibrentasvir | The serum concentration of Romidepsin can be increased when it is combined with Pibrentasvir. |
| Pimavanserin | The metabolism of Romidepsin can be decreased when combined with Pimavanserin. |
| Pimozide | The metabolism of Pimozide can be decreased when combined with Romidepsin. |
| Pinaverium | The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Romidepsin. |
| Piperaquine | The metabolism of Romidepsin can be decreased when combined with Piperaquine. |
| Pitolisant | The serum concentration of Romidepsin can be decreased when it is combined with Pitolisant. |
| Pomalidomide | The serum concentration of Pomalidomide can be increased when it is combined with Romidepsin. |
| Ponatinib | The serum concentration of Romidepsin can be increased when it is combined with Ponatinib. |
| Ponesimod | The risk or severity of bradycardia can be increased when Ponesimod is combined with Romidepsin. |
| Posaconazole | The metabolism of Romidepsin can be decreased when combined with Posaconazole. |
| Pralsetinib | The serum concentration of Romidepsin can be increased when it is combined with Pralsetinib. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Pramocaine. |
| Prasugrel | The metabolism of Prasugrel can be decreased when combined with Romidepsin. |
| Pravastatin | The serum concentration of Romidepsin can be increased when it is combined with Pravastatin. |
| Praziquantel | The metabolism of Romidepsin can be decreased when combined with Praziquantel. |
| Prednisolone | The metabolism of Romidepsin can be increased when combined with Prednisolone. |
| Prednisolone | The metabolism of Romidepsin can be increased when combined with Prednisolone acetate. |
| Prednisolone phos | The serum concentration of Romidepsin can be decreased when it is combined with Prednisolone phosphate. |
| Prednisone acetate | The metabolism of Romidepsin can be increased when combined with Prednisone acetate. |
| Pregabalin | The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Romidepsin. |
| Prenylamine | The risk or severity of QTc prolongation can be increased when Prenylamine is combined with Romidepsin. |
| Pretomanid | The serum concentration of Romidepsin can be increased when it is combined with Pretomanid. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Prilocaine. |
| Primaquine | The metabolism of Romidepsin can be decreased when combined with Primaquine. |
| Primidone | The metabolism of Romidepsin can be increased when combined with Primidone. |
| Probenecid | The metabolism of Romidepsin can be increased when combined with Probenecid. |
| Probucol | The risk or severity of QTc prolongation can be increased when Probucol is combined with Romidepsin. |
| Procainamide | The risk or severity of QTc prolongation can be increased when Procainamide is combined with Romidepsin. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Procaine. |
| Prochlorperazine | The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Romidepsin. |
| Progesterone | The metabolism of Romidepsin can be decreased when combined with Progesterone. |
| Promazine | The risk or severity of QTc prolongation can be increased when Promazine is combined with Romidepsin. |
| Promethazine | The risk or severity of QTc prolongation can be increased when Promethazine is combined with Romidepsin. |
| Propafenone | The serum concentration of Romidepsin can be increased when it is combined with Propafenone. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Proparacaine. |
| Propofol | The metabolism of Romidepsin can be decreased when combined with Propofol. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Propoxycaine. |
| Propranolol | The metabolism of Romidepsin can be decreased when combined with Propranolol. |
| Protriptyline | The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Romidepsin. |
| Quazepam | The metabolism of Romidepsin can be decreased when combined with Quazepam. |
| Quetiapine | The risk or severity of QTc prolongation can be increased when Quetiapine is combined with Romidepsin. |
| Quinidine | The serum concentration of Romidepsin can be increased when it is combined with Quinidine. |
| Quinine | The serum concentration of Romidepsin can be increased when it is combined with Quinine. |
| Quinupristin | The metabolism of Romidepsin can be decreased when combined with Quinupristin. |
| Raloxifene | The metabolism of Romidepsin can be decreased when combined with Raloxifene. |
| Ranolazine | The serum concentration of Romidepsin can be increased when it is combined with Ranolazine. |
| Regorafenib | The serum concentration of Romidepsin can be increased when it is combined with Regorafenib. |
| Relugolix | The risk or severity of QTc prolongation can be increased when Relugolix is combined with Romidepsin. |
| Remdesivir | The metabolism of Romidepsin can be decreased when combined with Remdesivir. |
| Reserpine | The serum concentration of Romidepsin can be increased when it is combined with Reserpine. |
| Revefenacin | The serum concentration of Romidepsin can be increased when it is combined with Revefenacin. |
| Ribociclib | The metabolism of Romidepsin can be decreased when combined with Ribociclib. |
| Rifabutin | The metabolism of Romidepsin can be increased when combined with Rifabutin. |
| Rifampicin | The serum concentration of Romidepsin can be increased when it is combined with Rifampicin. |
| Rifamycin | The serum concentration of Romidepsin can be increased when it is combined with Rifamycin. |
| Rifapentine | The metabolism of Romidepsin can be increased when combined with Rifapentine. |
| Rilonacept | The metabolism of Romidepsin can be increased when combined with Rilonacept. |
| Rilpivirine | The metabolism of Romidepsin can be decreased when combined with Rilpivirine. |
| Rimegepant | The serum concentration of Romidepsin can be increased when it is combined with Rimegepant. |
| Riociguat | The serum concentration of Romidepsin can be increased when it is combined with Riociguat. |
| Ripretinib | The serum concentration of Romidepsin can be increased when it is combined with Ripretinib. |
| Risperidone | The risk or severity of QTc prolongation can be increased when Risperidone is combined with Romidepsin. |
| Ritonavir | The serum concentration of Romidepsin can be increased when it is combined with Ritonavir. |
| Rivaroxaban | The serum concentration of Romidepsin can be increased when it is combined with Rivaroxaban. |
| Rofecoxib | The metabolism of Romidepsin can be increased when combined with Rofecoxib. |
| Roflumilast | The metabolism of Romidepsin can be decreased when combined with Roflumilast. |
| Rolapitant | The serum concentration of Romidepsin can be increased when it is combined with Rolapitant. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Ropivacaine. |
| Rosoxacin | The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Romidepsin. |
| Rosuvastatin | The metabolism of Romidepsin can be decreased when combined with Rosuvastatin. |
| Roxithromycin | The metabolism of Romidepsin can be decreased when combined with Roxithromycin. |
| Rucaparib | The metabolism of Romidepsin can be decreased when combined with Rucaparib. |
| Rufinamide | The metabolism of Romidepsin can be increased when combined with Rufinamide. |
| Rupatadine | The risk or severity of QTc prolongation can be increased when Rupatadine is combined with Romidepsin. |
| Sacubitril | The excretion of Romidepsin can be decreased when combined with Sacubitril. |
| Salbutamol | The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Romidepsin. |
| Salmeterol | The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Romidepsin. |
| Sapropterin | The serum concentration of Romidepsin can be increased when it is combined with Sapropterin. |
| Saquinavir | The metabolism of Romidepsin can be decreased when combined with Saquinavir. |
| Sarecycline | The serum concentration of Romidepsin can be increased when it is combined with Sarecycline. |
| Sarilumab | The metabolism of Romidepsin can be increased when combined with Sarilumab. |
| Satralizumab | The serum concentration of Romidepsin can be decreased when it is combined with Satralizumab. |
| Saxagliptin | The metabolism of Saxagliptin can be decreased when combined with Romidepsin. |
| Secobarbital | The metabolism of Romidepsin can be increased when combined with Secobarbital. |
| Secukinumab | The metabolism of Romidepsin can be increased when combined with Secukinumab. |
| Selegiline | The metabolism of Romidepsin can be decreased when combined with Selegiline. |
| Selexipag | The serum concentration of Romidepsin can be increased when it is combined with Selexipag. |
| Selinexor | The excretion of Romidepsin can be decreased when combined with Selinexor. |
| Selumetinib | The serum concentration of Romidepsin can be increased when it is combined with Selumetinib. |
| Sertraline | The metabolism of Romidepsin can be decreased when combined with Sertraline. |
| Sevoflurane | The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Romidepsin. |
| Sildenafil | The serum concentration of Romidepsin can be increased when it is combined with Sildenafil. |
| Silodosin | The serum concentration of Romidepsin can be increased when it is combined with Silodosin. |
| Siltuximab | The metabolism of Romidepsin can be increased when combined with Siltuximab. |
| Simeprevir | The serum concentration of Romidepsin can be increased when it is combined with Simeprevir. |
| Simvastatin | The serum concentration of Romidepsin can be increased when it is combined with Simvastatin. |
| Siponimod | The metabolism of Romidepsin can be decreased when combined with Siponimod. |
| Sirolimus | The metabolism of Sirolimus can be decreased when combined with Romidepsin. |
| Sitagliptin | The serum concentration of Romidepsin can be increased when it is combined with Sitagliptin. |
| Sitaxentan | The metabolism of Romidepsin can be decreased when combined with Sitaxentan. |
| Sofosbuvir | The serum concentration of Romidepsin can be increased when it is combined with Sofosbuvir. |
| Solifenacin | The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Romidepsin. |
| Somatostatin | The metabolism of Romidepsin can be decreased when combined with Somatostatin. |
| Somatrogon | The metabolism of Romidepsin can be increased when combined with Somatrogon. |
| Sorafenib | The risk or severity of QTc prolongation can be increased when Romidepsin is combined with Sorafenib. |
| Sotagliflozin | The serum concentration of Romidepsin can be increased when it is combined with Sotagliflozin. |
| Sotalol | The risk or severity of QTc prolongation can be increased when Sotalol is combined with Romidepsin. |
| Sotorasib | The serum concentration of Romidepsin can be decreased when it is combined with Sotorasib. |
| Sparfloxacin | The risk or severity of QTc prolongation can be increased when Sparfloxacin is combined with Romidepsin. |
| St. John’s Wort | The serum concentration of Romidepsin can be decreased when it is combined with St. John’s Wort. |
| Stiripentol | The metabolism of Romidepsin can be decreased when combined with Stiripentol. |
| Sulfamethoxazole | The metabolism of Romidepsin can be decreased when combined with Sulfamethoxazole. |
| Sulfaphenazole | The metabolism of Romidepsin can be decreased when combined with Sulfaphenazole. |
| Sulfasalazine | The excretion of Romidepsin can be decreased when combined with Sulfasalazine. |
| Sulfinpyrazone | The metabolism of Romidepsin can be increased when combined with Sulfinpyrazone. |
| Sulfisoxazole | The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Romidepsin. |
| Sulpiride | The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Romidepsin. |
| Sultopride | The risk or severity of QTc prolongation can be increased when Sultopride is combined with Romidepsin. |
| Sunitinib | The metabolism of Sunitinib can be decreased when combined with Romidepsin. |
| Suvorexant | The serum concentration of Romidepsin can be increased when it is combined with Suvorexant. |
| Tacrolimus | The serum concentration of Romidepsin can be increased when it is combined with Tacrolimus. |
| Tadalafil | The metabolism of Romidepsin can be decreased when combined with Tadalafil. |
| Talazoparib | The serum concentration of Talazoparib can be increased when it is combined with Romidepsin. |
| Tamoxifen | The serum concentration of Romidepsin can be increased when it is combined with Tamoxifen. |
| Tasimelteon | The metabolism of Romidepsin can be decreased when combined with Tasimelteon. |
| Tazemetostat | The metabolism of Romidepsin can be decreased when combined with Tazemetostat. |
| Technetium | The serum concentration of Romidepsin can be increased when it is combined with Technetium Tc-99m sestamibi. |
| Tecovirimat | The metabolism of Romidepsin can be increased when combined with Tecovirimat. |
| Tegafur | The metabolism of Tegafur can be decreased when combined with Romidepsin. |
| Tegaserod | The serum concentration of Romidepsin can be increased when it is combined with Tegaserod. |
| Telaprevir | The metabolism of Romidepsin can be decreased when combined with Telaprevir. |
| Telavancin | The risk or severity of QTc prolongation can be increased when Telavancin is combined with Romidepsin. |
| Telithromycin | The metabolism of Romidepsin can be decreased when combined with Telithromycin. |
| Telotristat ethyl | The serum concentration of Romidepsin can be decreased when it is combined with Telotristat ethyl. |
| Temsirolimus | The serum concentration of Romidepsin can be increased when it is combined with Temsirolimus. |
| Teniposide | The metabolism of Romidepsin can be decreased when combined with Teniposide. |
| Tenofovir alafen | The metabolism of Romidepsin can be decreased when combined with Tenofovir alafenamide. |
| Tenofovir disoproxil | The serum concentration of Romidepsin can be increased when it is combined with Tenofovir disoproxil. |
| Tepotinib | The serum concentration of Romidepsin can be increased when it is combined with Tepotinib. |
| Terbinafine | The metabolism of Romidepsin can be increased when combined with Terbinafine. |
| Terbutaline | The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Romidepsin. |
| Terfenadine | The metabolism of Romidepsin can be decreased when combined with Terfenadine. |
| Terlipressin | The risk or severity of QTc prolongation can be increased when Terlipressin is combined with Romidepsin. |
| Testosterone | The metabolism of Romidepsin can be increased when combined with Testosterone. |
| Testosterone | The metabolism of Testosterone cypionate can be decreased when combined with Romidepsin. |
| Testosterone | The metabolism of Testosterone enanthate can be decreased when combined with Romidepsin. |
| Tetrabenazine | The risk or severity of QTc prolongation can be increased when Tetrabenazine is combined with Romidepsin. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Tetracaine. |
| Tetracycline | The metabolism of Romidepsin can be decreased when combined with Tetracycline. |
| Tezacaftor | The serum concentration of Romidepsin can be increased when it is combined with Tezacaftor. |
| Thalidomide | The metabolism of Romidepsin can be increased when combined with Thalidomide. |
| Thiamylal | The metabolism of Romidepsin can be increased when combined with Thiamylal. |
| Thioridazine | The risk or severity of QTc prolongation can be increased when Thioridazine is combined with Romidepsin. |
| Thiosulfuric acid | The metabolism of Romidepsin can be increased when combined with Thiosulfuric acid. |
| Thiotepa | The metabolism of Romidepsin can be decreased when combined with Thiotepa. |
| Thiothixene | The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Romidepsin. |
| Ticagrelor | The serum concentration of Romidepsin can be increased when it is combined with Ticagrelor. |
| Ticlopidine | The metabolism of Romidepsin can be decreased when combined with Ticlopidine. |
| Timolol | The risk or severity of QTc prolongation can be increased when Timolol is combined with Romidepsin. |
| Tipranavir | The metabolism of Romidepsin can be decreased when combined with Tipranavir. |
| Tivozanib | The serum concentration of Romidepsin can be increased when it is combined with Tivozanib. |
| Tizanidine | The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Romidepsin. |
| Tocilizumab | The metabolism of Romidepsin can be increased when combined with Tocilizumab. |
| Tolterodine | The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Romidepsin. |
| Tolvaptan | The serum concentration of Tolvaptan can be increased when it is combined with Romidepsin. |
| Topiramate | The metabolism of Romidepsin can be increased when combined with Topiramate. |
| Topotecan | The serum concentration of Topotecan can be increased when it is combined with Romidepsin. |
| Toremifene | The serum concentration of Romidepsin can be increased when it is combined with Toremifene. |
| Tramadol | The metabolism of Romidepsin can be decreased when combined with Tramadol. |
| Trastuzumab | The metabolism of Trastuzumab emtansine can be decreased when combined with Romidepsin. |
| Trazodone | The risk or severity of QTc prolongation can be increased when Trazodone is combined with Romidepsin. |
| Treprostinil | The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Romidepsin. |
| Tretinoin | The metabolism of Romidepsin can be decreased when combined with Tretinoin. |
| Triamcinolone | The metabolism of Romidepsin can be increased when combined with Triamcinolone. |
| Triazolam | The metabolism of Romidepsin can be decreased when combined with Triazolam. |
| Triclabendazole | The metabolism of Romidepsin can be decreased when combined with Triclabendazole. |
| Trilaciclib | The serum concentration of Romidepsin can be increased when it is combined with Trilaciclib. |
| Trimebutine | The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Romidepsin. |
| Trimethadione | The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Romidepsin. |
| Trimipramine | The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Romidepsin. |
| Triprolidine | The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Romidepsin. |
| Triptorelin | The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Romidepsin. |
| Troglitazone | The metabolism of Romidepsin can be increased when combined with Troglitazone. |
| Troleandomycin | The metabolism of Romidepsin can be decreased when combined with Troleandomycin. |
| Trovafloxacin | The risk or severity of QTc prolongation can be increased when Trovafloxacin is combined with Romidepsin. |
| Tucatinib | Tucatinib may decrease the excretion rate of Romidepsin which could result in a higher serum level. |
| Ubrogepant | The serum concentration of Romidepsin can be increased when it is combined with Ubrogepant. |
| Udenafil | The metabolism of Udenafil can be decreased when combined with Romidepsin. |
| Umbralisib | The serum concentration of Romidepsin can be increased when it is combined with Umbralisib. |
| Umeclidinium | The serum concentration of Romidepsin can be increased when it is combined with Umeclidinium. |
| Valbenazine | The metabolism of Valbenazine can be decreased when combined with Romidepsin. |
| Valproic acid | The metabolism of Romidepsin can be decreased when combined with Valproic acid. |
| Vandetanib | The serum concentration of Romidepsin can be increased when it is combined with Vandetanib. |
| Vardenafil | The serum concentration of Romidepsin can be increased when it is combined with Vardenafil. |
| Velpatasvir | The serum concentration of Romidepsin can be increased when it is combined with Velpatasvir. |
| Vemurafenib | The serum concentration of Romidepsin can be increased when it is combined with Vemurafenib. |
| Venetoclax | The serum concentration of Romidepsin can be increased when it is combined with Venetoclax. |
| Verapamil | The serum concentration of Romidepsin can be increased when it is combined with Verapamil. |
| Vernakalant | The risk or severity of QTc prolongation can be increased when Vernakalant is combined with Romidepsin. |
| Vilanterol | The risk or severity of QTc prolongation can be increased when Vilanterol is combined with Romidepsin. |
| Viloxazine | The metabolism of Romidepsin can be decreased when combined with Viloxazine. |
| Vinblastine | The metabolism of Romidepsin can be increased when combined with Vinblastine. |
| Vincristine | The metabolism of Vincristine can be decreased when combined with Romidepsin. |
| Vinflunine | The serum concentration of Vinflunine can be increased when it is combined with Romidepsin. |
| Vitamin E | The metabolism of Romidepsin can be increased when combined with Vitamin E. |
| Voclosporin | The serum concentration of Romidepsin can be increased when it is combined with Voclosporin. |
| Vonoprazan | The metabolism of Vonoprazan can be decreased when combined with Romidepsin. |
| Vorapaxar | The serum concentration of Romidepsin can be increased when it is combined with Vorapaxar. |
| Voriconazole | The metabolism of Romidepsin can be decreased when combined with Voriconazole. |
| Vorinostat | The risk or severity of gastrointestinal bleeding and thrombocytopenia can be increased when Romidepsin is combined with Vorinostat. |
| Vortioxetine | The metabolism of Vortioxetine can be decreased when combined with Romidepsin. |
| Voxelotor | The serum concentration of Romidepsin can be increased when it is combined with Voxelotor. |
| Voxilaprevir | The serum concentration of Romidepsin can be increased when it is combined with Voxilaprevir. |
| Warfarin | Romidepsin may increase the anticoagulant activities of Warfarin. |
| Zafirlukast | The metabolism of Romidepsin can be decreased when combined with Zafirlukast. |
| Zaleplon | The metabolism of Romidepsin can be decreased when combined with Zaleplon. |
| Zanubrutinib | The metabolism of Zanubrutinib can be decreased when combined with Romidepsin. |
| Zimelidine | The metabolism of Romidepsin can be decreased when combined with Zimelidine. |
| Ziprasidone | The risk or severity of QTc prolongation can be increased when Romidepsin is combined with Ziprasidone. |
| Zonisamide | The serum concentration of Romidepsin can be increased when it is combined with Zonisamide. |
| Zuclopenthixol | The risk or severity of QTc prolongation can be increased when Zuclopenthixol is combined with Romidepsin. |
Pregnancy and Lactation
AU TGA pregnancy category: D
US FDA pregnancy category: Not assigned.
Pregnancy
Based on its mechanism of action and findings from animal studies, Romidepsin Injection can cause embryofetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1)]. There are no available data on romidepsin use in pregnant women to inform a drug associated risk of major birth defects and miscarriage. In an animal reproductive study, romidepsin was embryocidal and caused adverse developmental outcomes including embryo-fetal toxicity and malformations at exposures below those in patients at the recommended dose (see Data). Advise pregnant women of the potential risk to a fetus and to avoid becoming pregnant while receiving romidepsin and for at least 1 month after the last dose. The background risk of major birth defects and miscarriage for the indicated population is unknown. All
pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Lactation
There are no data on the presence of romidepsin or its metabolites in human milk, the effects on the breastfed child, or the effects on milk production. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in the breastfed child, advise lactating women not to breastfeed during treatment with Romidepsin Injection and for at least 1 week after the last dose.
Why is this medication prescribed?
Romidepsin injection is used to treat cutaneous T-cell lymphoma (CTCL; a group of cancers of the immune system that first appear as skin rashes) in people who have already been treated with at least one other medication. Romidepsin injection is also used to treat peripheral T-cell lymphoma (PTCL; a type of non-Hodgkin’s lymphoma) in people who have already been treated with at least one other medication. Romidepsin injection is in a class of medications called histone deacetylase (HDAC) inhibitors. It works by slowing the growth of cancer cells.
How should this medicine be used?
Romidepsin injection comes as a powder to be mixed with liquid to be injected intravenously (into a vein) over a 4-hour period by a doctor or nurse. It is usually given on days 1, 8, and 15 of a 28-day cycle. This cycle may be repeated as long as the medication continues to work and does not cause severe side effects.
Talk to your doctor about any side effects you experience during your treatment with romidepsin injection. If you experience certain severe side effects, your doctor may stop your treatment permanently or temporarily and/or may decrease your dose. Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient. This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.
What special precautions should I follow?
Before receiving romidepsin injection,
- tell your doctor and pharmacist if you are allergic to romidepsin injection, any other medications, or any of the ingredients in romidepsin injection. Ask your pharmacist or check the patient information for a list of the ingredients.
- tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: certain antibiotics such as clarithromycin (Biaxin), erythromycin (E.E.S., E-Mycin, Erythrocin), moxifloxacin (Avelox), and telithromycin (Ketek); anticoagulants (blood thinners) such as warfarin (Coumadin, Jantoven); antifungals such as itraconazole (Sporanox), ketoconazole (Nizoral), and voriconazole (Vfend); cisapride (Propulsid) (not available in the U.S.); dexamethasone; medications for human immunodeficiency virus (HIV) such as atazanavir (Reyataz), indinavir (Crixivan), nelfinavir (Viracept), ritonavir (in Kaletra, Norvir), and saquinavir (Invirase); medications for irregular heartbeat such as amiodarone (Cordarone), disopyramide (Norpace), dofetilide (Tikosyn), procainamide (Procanbid, Pronestyl), quinidine (Quinidex), and sotalol (Betapace, Betapace AF); certain medications for seizures such as carbamazepine (Epitol, Equetro, Tegretol), phenobarbital, and phenytoin (Dilantin); nefazodone; pimozide (Orap); rifabutin (Mycobutin); rifampin (Rifadin, in Rifamate, in Rifater, Rimactane); rifapentine (Priftin); sparfloxacin (Zagam); or thioridazine (Mellaril). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with romidepsin injection, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
- tell your doctor what herbal products you are taking, especially St. John’s wort.
- tell your doctor if you have nausea, vomiting, or diarrhea before you begin your treatment with romidepsin injection. Also tell your doctor if you have or have ever had a prolonged QT interval (a rare heart problem that may cause irregular heartbeat, fainting, or sudden death), an irregular or fast heartbeat, too much or too little potassium or magnesium in your blood, hepatitis B (HBV; a virus that infects the liver and may cause severe liver damage or liver cancer), Epstein Barr virus (EBV; a herpes virus that causes infectious mononucleosis and is associated with certain cancers), or liver, kidney, or heart disease.
- tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. Your doctor may check to see if you are pregnant before you begin your treatment. You should use birth control to prevent pregnancy during your treatment with romidepsin injection and for at least one month after your final dose. However, you should not use hormonal (estrogen) contraceptives (birth control pills, patches, rings, implants, or injections) because romidepsin injection may stop these medications from working as they should. If you are a male with a female partner who could become pregnant, be sure to use birth control during your treatment with romidepsin injection and for at least one month after your final dose. Talk to your doctor about birth control methods that you can use. If you become pregnant while receiving romidepsin injection, call your doctor. Romidepsin injection may harm the fetus. You should not breastfeed during your treatment with romidepsin injection and for at least 1 week after your final dose.
- if you are having surgery, including dental surgery, tell the doctor or dentist that you are receiving romidepsin injection.
References
